Alviva Biopharmaceuticals

Alviva Biopharmaceuticals is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics for cardiovascular and renal diseases. The company’s primary focus is on "designer" natriuretic peptides, which are engineered to optimize the therapeutic properties of endogenous hormones. Its lead program, ALV-107, is a subcutaneously administered agonist of the Natriuretic peptide receptor-A (NPR-A) intended to treat heart failure by improving hemodynamics and renal function. Alviva leverages foundational research and intellectual property licensed from the Mayo Clinic. The company aims to provide long-acting, convenient treatment options for patients with chronic cardiac conditions. By utilizing subcutaneous delivery, Alviva seeks to address the limitations of traditional intravenous natriuretic peptide therapies.